Identification of ways to develop the pharmaceutical industry in Russia under sanctions, taking into account the available alternatives

The purpose of this article is to identify ways to develop the pharmaceutical industry in Russia under sanctions, taking into account the available alternatives, among which parallel imports, the production of generics, as well as accelerated development of the national pharmaceutical industry in the direction of increasing its innovativeness are identified. The urgency of this problem is connected with the fact that the sanctions pressure has created prerequisites for the appearance of a shortage for certain commodity items that were previously supplied from abroad, and in the current conditions their entry into the Russian market is limited. As a result of the analysis carried out by the authors of this article, it was found that the release of generics, as well as the use of parallel imports, cannot completely solve this problem, although these areas of development are able to temporarily correct the market situation by supporting the domestic market. At the same time, the accelerated development of the national pharmaceutical industry in the direction of increasing its innovativeness is able to solve the problem raised in the long term, in connection with which the article provides recommendations on the directions of implementation of this strategy for the development of the pharmaceutical market in the Russian Federation. The role of the state in achieving the development of the national pharmaceutical industry in the direction of increasing its innovativeness is highlighted, the directions of state participation in this process based on the use of the SWOT methodology are highlighted - analysis, it is determined that the main goal of the long-term development strategy of Russian pharmacy (until 2030) is to create a new generation of enterprises for the production of pharmaceutical substances and finished dosage forms (synthetic drugs, nanostructured forms of medicines based on cellular biotechnologies), as well as to achieve 90 % of the production level of all domestic medicines necessary for classes of diseases.